TY - JOUR
T1 - Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma
AU - Hamamoto, Yasuo
AU - Nojima, Masanori
AU - Aoki, Yu
AU - Suzuki, Takeshi
AU - Kawasaki, Kenta
AU - Hirata, Kenro
AU - Sukawa, Yasutaka
AU - Kasuga, Akira
AU - Kawakubo, Hirofumi
AU - Takeuchi, Hiroya
AU - Murakami, Koji
AU - Takaishi, Hiromasa
AU - Kanai, Takanori
AU - Kitagawa, Yuko
N1 - Funding Information:
We thank the members of the weekly oncology board upper gastrointestinal meeting who participated in this study. Yuko Kitagawa has conflicts of interest to declare with regard to this manuscript: Ethicon, Ono Pharmaceutical co., Taiho Pharma, Chugai Pharmaceutical co., Asahi Kasei Pharma, Otsuka Pharmaceutical Co., Kyowa Hakko Kirin Co., Daiichi Sankyo Co., Takeda Pharmaceutical Co. Nippon Boehringer Ingelheim Co., Novartis Pharma., Pfeizer Japan, Merck Serono Co., Yakult Honsha Co., Terumo Corporation, Torii Pharmaceutical Co., Astra Zeneca. Yasuo Hamamoto has conflicts of interest to declare with regard to this manuscript: Chughai-pharm. Ono Pharmaceutical co., Taiho Pharma., Yakult honsha. This work was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (Grant No. 16K08880).
Funding Information:
Funding This work was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (Grant No. 16K08880).
Publisher Copyright:
© 2017, The Author(s).
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background: Identifying clinical resectability of locally advanced esophageal squamous cell carcinoma (ESCC) is important, although inter-evaluator heterogeneity (IEH) could exist, especially in borderline resectable (BLR) cases. To investigate the extent of heterogeneity, we conducted clinical diagnostic imaging questionnaires. Materials and methods: Five cases with clinical T3 or T4 cases, which were treated with neo-adjuvant triplet chemotherapy followed by surgery, were selected as the model. These cases were divided into two groups: curative resected cases (#1–#3) and non-curative resected cases (#4 and #5). Only imaging slides were shown without any information about patient characteristics or clinical course. The evaluators consisted of surgeons (staff and non-staff), medical oncologists, and an imaging radiologist; a total of 25 medical staff answered the questionnaire. Two questions (1: clinical T stage before chemotherapy, 2: resectability after chemotherapy) were answered. Occupational differences were assessed by comparing the results to the imaging radiologist. Results: IEH was observed for clinical diagnosis before chemotherapy in one case (clinical T4: 52%, clinical T3: 48%). In the other cases, most evaluators diagnosed them as clinical T4, with 76–88% agreement. IEH for clinical resectability after chemotherapy was relatively small. Occupational IEH was observed in both before and after chemotherapy. Conclusion: IEH in decisions about treating BLR cases in ESCC should be considered in clinical practice. Multi-disciplinary teams are essential to overcome this problem.
AB - Background: Identifying clinical resectability of locally advanced esophageal squamous cell carcinoma (ESCC) is important, although inter-evaluator heterogeneity (IEH) could exist, especially in borderline resectable (BLR) cases. To investigate the extent of heterogeneity, we conducted clinical diagnostic imaging questionnaires. Materials and methods: Five cases with clinical T3 or T4 cases, which were treated with neo-adjuvant triplet chemotherapy followed by surgery, were selected as the model. These cases were divided into two groups: curative resected cases (#1–#3) and non-curative resected cases (#4 and #5). Only imaging slides were shown without any information about patient characteristics or clinical course. The evaluators consisted of surgeons (staff and non-staff), medical oncologists, and an imaging radiologist; a total of 25 medical staff answered the questionnaire. Two questions (1: clinical T stage before chemotherapy, 2: resectability after chemotherapy) were answered. Occupational differences were assessed by comparing the results to the imaging radiologist. Results: IEH was observed for clinical diagnosis before chemotherapy in one case (clinical T4: 52%, clinical T3: 48%). In the other cases, most evaluators diagnosed them as clinical T4, with 76–88% agreement. IEH for clinical resectability after chemotherapy was relatively small. Occupational IEH was observed in both before and after chemotherapy. Conclusion: IEH in decisions about treating BLR cases in ESCC should be considered in clinical practice. Multi-disciplinary teams are essential to overcome this problem.
KW - Esophageal cancer
KW - Heterogeneity
KW - Resectability
UR - http://www.scopus.com/inward/record.url?scp=85019851421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019851421&partnerID=8YFLogxK
U2 - 10.1007/s10388-017-0580-x
DO - 10.1007/s10388-017-0580-x
M3 - Article
C2 - 28983229
AN - SCOPUS:85019851421
SN - 1612-9059
VL - 14
SP - 324
EP - 332
JO - Esophagus
JF - Esophagus
IS - 4
ER -